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The evidence underpinning public health policy is often of low quality, leading to inconsistencies in recommended interventions.
One example is the divergence in national policies across Europe for managing contacts of invasive meningococcal disease. Aiming
to develop consistent guidance at the European level, a group of experts reviewed the literature and formulated recommendations.
The group defined eight priority research questions, searched the literature, and formulated recommendations using GRADE
methodology. Five of the research questions are discussed in this paper. After taking into account quality of evidence, benefit,
harm, value, preference, burden on patient of the intervention, and resource implications, we made four strong recommendations
and five weak recommendations for intervention. Strong recommendations related not only to one questionwith very low quality of
evidence as well as to two questions withmoderate to high quality of evidence.Theweak recommendations related to two questions
with low and very low quality of evidence but also to one questionwithmoderate quality of evidence. GRADEmethodology ensures
a transparent process and explicit recognition of additional factors that should be considered when making recommendations for
policy. This approach can be usefully applied to many areas of public health policy where evidence quality is often low.
1. Introduction
The incidence of invasive meningococcal disease (IMD),
caused by Neisseria meningitidis, is low in Europe, but case
fatality is high (0.8 cases/100,000 inhabitants and 8.7%, resp.,
in 2011) [1]. Outbreaks of IMD may generate significant
anxiety in the population, and even a single case may have
important public health implications [2, 3].N. meningitidis is
transmitted from person to person and the risk of disease is
highest in contacts from the same household as a case [4, 5].
In 2007, a European survey showed that recommendations
for chemoprophylaxis to eliminate nasopharyngeal carriage
in close contacts of IMD cases varied across Europe, in
particular regarding the type of antibiotic and the groups that
should be targeted [6, 7]. Discrepancies were partly due to
differences in policy, medical practices, and health systems
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but could also be explained by uncertainty surrounding the
effectiveness of preventive measures or the differences in
methods used to develop recommendations [6].
Divergences in national policies are particularly prob-
lematic in cross-border settings, as they lead to differences
in disease management among population groups with the
same exposure. For instance, passengers sharing an aeroplane
flight with a case of IMD might or might not receive
chemoprophylaxis depending on their country of residence
[8].The EuropeanCentre for Disease Prevention andControl
(ECDC) therefore commissioned a group of experts to
develop guidance for European countries on themanagement
of contacts of IMD.
It was clear from the outset that high quality evidence in
this area would be limited as in many areas of public health
[9].This is because randomized clinical trials on public health
interventions are often difficult to organize (particularly
when incidence of the outcome is low) and the use of placebo
is no longer considered ethical when the intervention studied
is already a recommended standard of care. In addition,
evidence may be indirect as when only surrogate (proxy)
endpoints are available. Therefore, information often comes
from observational studies that are more prone to bias
and are considered to provide a lower quality of evidence
[10]. However, such studies can still be used in developing
recommendations if systematically researched and graded
appropriately [11]. In addition, evidence obtained for a public
health intervention in one countrymay not be fully applicable
to another setting, as public health interventions are strongly
dependent not only on the epidemiological context but also
on cultural and economic context of countries in which they
are implemented.
Here we share our experience and lessons learned in
using different types and quality of evidence to develop
guidance on the public health management of IMD for
European countries within a short time period using GRADE
methodology. The aim of this guidance, available on the
ECDC website, was to assist countries across Europe in
making decisions about appropriate measures to control and
prevent IMD in contacts of cases at national and subnational
levels [12].
2. Description of the Process
We adapted existing methods for producing evidence-based
guidelines to dealwith the short time frame and the scarcity of
direct evidence (see Section 2.12) [10, 13–17]. The main steps
are described below.
2.1. Setting Up Expert Groups. We set up a consortium
of national experts: four in the area of epidemiology and
public health surveillance and one in the area of micro-
biology of meningococcal disease. The consortium mem-
bers represented five EU countries, previously involved in
the assessment of national practices for IMD management
across the European Union [6]. The consortium identified
research questions, developed protocols, identified, assessed,
and graded evidence, and formulated and graded recommen-
dations. This work was contracted for completion within 6
months, had a budget of 20,000 Euros, and was conducted
through two face-to-face meetings, three teleconferences,
and close to 500 e-mail exchanges. Each member of the
expert group completed a declaration of potential conflict of
interests.
The consortium identified other national epidemiologists
and microbiologists working with meningococcal disease
from all EU countries through two established European
networks (the European Meningococcal Disease Society and
the ECDC European Invasive Bacterial Diseases Surveillance
Network). These EU experts were asked to provide any
related grey literature and technical advice during the process.
Additionally, the consortium consulted two patient group
networks, both based in the United Kingdom, on patient-
related values and preferences.
2.2. Defining the Area of Guidance and Formulating the
Research Questions. The consortium defined research ques-
tions for guidance focused on the prevention of subsequent
cases following sporadic cases of IMD and based on the
needs identified through two previous surveys among public
health representatives of EU countries [6, 18]. Five research
questions for evidence assessment are discussed in this paper.
A summary of the evidence and recommendations for all
research questions can be found in the ECDC guidance [12].
Research Questions for Evidence Assessment
(A) What is the effectiveness of chemoprophylaxis to
a case of IMD before discharge from hospital in
preventing further cases of IMD?
(B) What is the effectiveness of chemoprophylaxis to
household contacts of an IMD case in preventing
further cases?
(C) What is the effectiveness of chemoprophylaxis to
contacts of an IMD case in pre-school and school
settings in preventing further cases?
(D) What is the effectiveness of chemoprophylaxis to
those sharing the same transport vehicle as an IMD
case in preventing further cases?
(E) Which antibiotic regimes are most effective in eradi-
cating carriage among adults, children and pregnant
women?
2.3. Defining the Methodology. We opted for GRADE (Grad-
ing of Recommendations Assessment, Development, and
Evaluation) methodology to assess evidence and produce
guidance; we used the GRADE guidance available at the time
of this study (2008-09) [14, 17, 19]. GRADEnot only considers
the balance between the benefits and harm and the quality
of evidence but also includes additional factors on which to
base recommendations, such as burden of the intervention
on the patient, patients’ values and preferences, and resource
implications, which were not addressed by a number of
other grading systems. GRADE also provides clear criteria to
qualify the strength of a recommendation. AlthoughGRADE
has been considered by some as being too resource intensive
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and difficult to apply in public health guidance, especially
under time constraint and when evidence is limited [20], it
is recognized by others to provide a systematic approach,
promote dialogue, and ensure documentation of the process
that leads to a given recommendation [21, 22]. This makes
decision-making more transparent. We referred to previ-
ous experience reported in two World Health Organization
(WHO) publications on rapid advice guidelines that made
use of GRADE methodology and to Cochrane guideline for
public health interventions [14, 15, 23].
The consortium developed protocols, templates, and
checklists for screening abstracts/papers retrieved in the
literature searches to ensure a homogenous process across
the research questions and across reviewers. The process was
also reviewed against the criteria for guideline development
as defined by the AGREE collaboration [16].
2.4. Search Strategy and Selection Criteria for Systematic
Reviews. When defining the most suitable terms for the
population, intervention, comparison, and outcome (PICO)
to define our research questions for the search strategy
(see examples in Table 1) [15], we took into account prior
knowledge and a preassessment of the literature. Our pre-
assessment suggested that measurements of direct outcomes
would not be available for several research questions due to
the low incidence of IMD. For these questions, we defined and
included proxy outcomes in our search strategy (see examples
below Section 2.5).
We defined inclusion and exclusion criteria for selecting
studies, applied to each research question. All European
languages were included to avoid publication biases. As most
of our studied interventions either were standard clinical
practice or involved rare outcomes, clinical trials had not
been conducted for ethical or logistical reasons. We thus did
not limit inclusion to experimental studies but also included
observational studies that involved comparison groups and
case series with at least 10 cases.
We searched MEDLINE, Embase, Global Health, the
Cochrane database of systematic reviews, and the Cochrane
central register of controlled trials. The search terms for
each question were agreed by at least two members of the
consortium. Due to the short time frame, we applied some
of the strategies previously used in rapid reviews by limiting
the search to the period from January 1990 to the date of
the literature search (December 2008) and giving priority
to systematic reviews [24]. If a relevant systematic review
was identified, we only considered abstracts published from
the date of search for the last review up to the end of
2008. If no relevant review was identified, we screened all
abstracts published from 1990 to 2008. We reviewed full
papers of abstracts identified as relevant. One reviewer only
was involved in reviewing abstracts and full papers of each
research question due to time constraints. In case of doubts,
ad hoc opinion of a second reviewer was requested.
We examined reference lists of the selected papers for
other relevant publications and searched Google Scholar
for citations of identified key papers. For instance, for the
research question on effectiveness of antibiotic regimens
(Question E), we found a nonindexed but peer reviewed trial
on antibiotic prophylaxis by using Google Scholar, though
this study had not been retrieved by a previous Cochrane
systematic review [25].
2.5. Use of Indirect Evidence. As studies measuring direct
evidence on outcomes could not be found in four of the five
research questions discussed in this paper, we defined and
searched for indirect evidence on outcomes. For example, the
relevant direct outcome for the question on the effectiveness
of chemoprophylaxis before hospital discharge in preventing
further cases among contacts (Question A) would be the
incidence of subsequent cases in household contacts of the
IMD patients who received antibiotics prior to discharge
from hospital. A prior systematic review did not identify
relevant studies measuring this outcome but showed that
eradicating nasopharyngeal carriage in household contacts
reduced the risk of further cases [7]. We thus searched
for data on the proxy outcome, that is, the prevalence of
meningococcal carriage in discharged patients (Table 1).
We also did not find direct evidence on the research
question regarding whether chemoprophylaxis of contacts in
school settings would prevent further cases (Question C).
However, we obtained indirect evidence by comparing the
risk of subsequent cases in school contacts (not receiving
chemoprophylaxis) with the background incidence rates of
IMD in the relevant population [26].
Even when the literature search provided direct evi-
dence on the benefits of an intervention (e.g., effectiveness
in preventing secondary cases), the evidence was often
insufficient on its harm. In particular, direct evidence on
the adverse events of antibiotics administered as chemo-
prophylaxis (Question E) was insufficient, but we found
and reviewed indirect evidence on adverse events of these
antibiotics when administered for indications other than
chemoprophylaxis (e.g., ciprofloxacin used in cystic fibrosis).
2.6. Analysis of Extracted Data. We extracted and summa-
rized the evidence on benefits and harm and prepared evi-
dence profiles. When possible, we pooled estimates retrieved
from selected studies. For instance, forQuestion B on chemo-
prophylaxis for household contacts, we extracted results
from a recent study published after a systematic review and
analysed these together with the three former studies from
the review [7, 27–29]. As the results of the four studies were
statistically homogeneous, we calculated a common pooled
estimate (Figure 1) [12]. In case of heterogeneity between
studies, we performed stratified analysis when possible. In
particular, analyses on the effectiveness of chemoprophylaxis
to contacts of an IMD case in preschool and school settings
(Question C) were stratified by each educational setting [26].
If the retrieved systematic reviews did not provide the
level of detail needed to calculate pooled estimates of
effectiveness or to fully answer the research questions, we
extracted the necessary data from primary studies when
appropriate. For instance, in the research question on antibi-
otic regimes for different subgroups (Question E), we identi-
fied Cochrane systematic review on antibiotics for preventing
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Figure 1: Estimate of effect of chemoprophylaxis to household
contacts following a sporadic IMD case.
meningococcal infections, but this review did not present
detailed analyses by antibiotic dosage and duration of therapy
and did not stratify estimates by subgroups such as children
and pregnant and lactating women [25]. We thus retrieved
the nine primary studies that involved different dosages,
treatment durations, and subgroups, extracted the required
data, and appraised the studies based on the full papers.
2.7. Reviewing and Grading Evidence. Evidence was classified
for all questions as either direct or indirect.We graded bodies
of evidence according to GRADE guidelines and classified
them as high, moderate, low, or very low, based on study
design and quality, inconsistency, indirectness, imprecision,
and strength of the association [17, 19]. In particular, wemade
a judgment of whether the evidence was sufficiently indirect
to warrant downgrading. For example, we downgraded the
quality of evidence for the four studies retrieved for the
research question on chemoprophylaxis for cases before
hospital discharge (Question A), as they measured a proxy
outcome, had very small study populations ranging from 14
to 51, and used different therapeutic antibiotic regimes. As
observational studies start with “low quality” evidence rating
according to GRADE [13], this led to classification of the
evidence quality to “very low.”
We found high or moderate quality evidence for only two
of the five research questions, that is, regarding chemopro-
phylaxis to household contacts (Question B) and antibiotic
regimes (Question E). Only low or very low quality of evi-
dence was found for the remaining three research questions
(Questions A, C, and D). Table 1 describes evidence review
and grading for three research questions (QuestionsA,D, and
E) for which the quality of evidence was very low (A and D)
or moderate to high (E).
2.8. Burden on Patient, Values, Preferences, and Resource
Implications. Because these factors varied across settings [21,
22], we first outlined, for each question, what should be
considered from the patients perspective as burden of the
intervention and their values and preferences and resource
implications in an EU setting. For instance, for the bur-
den of prophylactic antibiotics (Question E), we considered
for each antibiotic the potential side effects, inconvenience
(e.g., number of days of treatment) for contacts, ease of
administration, and the number of contacts needed to be
treated (where possible to calculate) to prevent one IMD
case among contacts according to each setting. We also
considered the implications of contact tracing, as this can
lead to considerable costs when, for instance, tracing close
contacts on the same aeroplane as an IMD case is required
(Question D) and may even not be feasible, for example, in
case of free seating.
We found little information in the literature on burden
of intervention perceived by patients and on their values
and preferences. We searched for alternative data sources:
for instance, information on perceived burden and values
was requested from EU experts and national IMD represen-
tatives as well as from two meningitis patient associations.
This confirmed that IMD is perceived as a severe disease
that generates a high level of anxiety, and thus prevention
measures are widely accepted, even if associated with some
level of discomfort.
2.9. Developing and Grading the Strength of Recommenda-
tions. The consortium met face-to-face to develop recom-
mendations according to GRADE, based on the quality of
evidence and the balance between the benefits and harm,
taking into account burden, values, preferences, and costs
(see examples in Table 1).
Recommendations were classified as strong or weak as
recommended by GRADE [10, 14, 17]. The GRADE guid-
ance available at the time of developing this guidance did
not provide an objective method for assessing the balance
between benefit, harm, burden, values, and costs [13, 17]. We
decided that the entire consortium should participate and
agree on this appraisal process and we included advice of two
patients’ groups regarding values and preferences related to
the recommendations. Based on these criteria, four strong
and five weak recommendations for intervention were made
for the five research questions. Strong recommendationswere
made not only in relation to two research questions with
moderate to high quality of evidence (Questions B and E) but
also in relation to one research question with very low quality
of evidence (Question A). The weak recommendations for
or against intervention referred not only to two research
questions with low or very low quality of evidence (Questions
C andD) but also to two aspects of one research questionwith
moderate quality of evidence (Question E).
The strong recommendation for which the quality of
evidence on the benefit was very low was related to the
research question on chemoprophylaxis of IMD cases before
hospital discharge (Question A). Despite the very low quality
evidence on the benefits, the consortium considered that
harm, cost, burden, and values were strongly in favour of the
intervention: the low cost of the intervention, the low number
of patients not treated with an eradicating antibiotic regimen
prior to discharge, and the potential benefit in reducing
risk from a life-threatening disease were balanced against
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limited harm from antibiotics (Table 1). In general, higher
quality evidence is more likely to be associated with strong
recommendations than lower quality evidence [11]. How-
ever, the GRADE methodology indicates that a particular
quality of evidence does not imply a particular strength of
recommendation. A number of public health guidances and
GRADE clinical guidelines issued strong recommendations
in the face of a very low quality of evidence [11, 13, 14,
23, 30]. WHO also considers that strong recommendations
can be made despite low or very low quality evidence in
specific circumstances, as it is the net result of all relevant
factors that are important [21]. For instance, WHO rapid
advice guidelines for management of sporadic human infec-
tion with avian influenza A (H5N1) virus made a strong
recommendation to treat H5N1 patients with oseltamivir,
although the quality of the underlying evidence was rated
as very low in part because of the severity of the disease
[23]. A recent review highlighted that over than half (55%)
of strong recommendations in WHO guidelines were based
on low or very low confidence in effect estimates [30]. A
GRADE guidance published after our review describes five
situations in which a strong recommendation is warranted
despite low or very low confidence in effect estimates [31].The
most relevant to our review was “when low quality evidence
suggests benefit in a life-threatening situation,” as all of
our recommendations aimed at preventing a life-threatening
invasive infection.
Consensus on the recommendations and grading of their
strengthwas difficult to reach regarding chemoprophylaxis in
day care settings (Question C). Here, the quality of evidence
was low, and divergent recommendations were in place in
the consortium members’ native countries. Thus each expert
was probably influenced by his/her existing national policy.
This highlighted that recommendations are built not only on
rigorous scientific reviews but also on expert interpretation
and judgment of the evidence. An advantage of the GRADE
approach is to promote useful dialogue and ensure trans-
parency by making these value judgments explicit [17, 21].
We involved stakeholders and potential users of the
guidance in the final steps. As our aim was to produce
guidance that could be adapted to the needs of different EU
countries, the draft document was circulated through EU
experts and patient groups and reviewed by representatives
of EU countries in the ECDC Advisory Forum.The feedback
from ECDC and EU experts on the draft report allowed
useful additions to the guidance [12]. For instance, we added
recommendations on use of antibiotics by lactating women
on request from representatives from a patient association.
2.10. Implications for Practice. We described how the guid-
ance would potentially change current practice in EU coun-
tries. For instance, for the research question (E) on effective-
ness of antibiotic regimens in IMD prophylaxis, we described
what policy changes would be required and potential obsta-
cles to the implementation of this guidance in a EU setting,
based on whether the intervention or the specific drug is
available and whether the recommended regimen differs
from those currently recommended. In particular, some
effective dosages did not correspond to recommendations
and formulations available in EU countries andwould require
a change in current guidance. For instance, high quality
evidence was available for the effectiveness of a single dose
of 750mg ciprofloxacin for the eradication of meningococcal
carriage. However, inmany countries, ciprofloxacin is recom-
mended as a 500mg single dose, although the effectiveness of
this lower dosage has not been assessed in a controlled trial.
2.11. Strengths of the Process. The guidance was successfully
completedwithin sixmonths andwas approved and endorsed
by ECDC in 2010 [12]. The GRADE approach allowed
transparent judgments on the quality of evidence and the
formulation of recommendations. Our process met most
of the criteria for guideline development as defined by the
AGREE collaboration (2003 version) [16]. We complied with
the following criteria: definition of the scope and purpose,
stakeholder involvement, rigor of development, clarity and
presentation, application, and editorial independence. On
the other hand, our review process did not fulfil criteria
pertaining to tools for application and audit.
An advantage of GRADE process in developing public
health recommendations is the integrated appraisal of related
values, preferences, burden to the patient, and resource
implications in addition to quality of evidence and the
balance between benefits and harm. Based on GRADE 2004–
08 guidance, we made strong recommendations for some
areas in which the quality of evidence was low or very
low. The long deliberations often required to arrive at final
agreement of recommendations were facilitated by frequent
communication, mainly by e-mail. It should be noted that
GRADEwork published later provides a systematic approach
by describing circumstances in which a strong recommen-
dation is warranted despite low or very low confidence in
effect estimates, but these were not available at the time of
developing our guidance [30, 31].
The influence of national policies on the judgment of each
consortiumexpert to formulate recommendations (described
above) was dealt with by explicitly discussing each recom-
mendation in the entire group. One advantage of having
experts from five EU countries in the consortium was also
that they had knowledge of current practices and health
systems when considering implications for practice of the
guidance.
The development of this guidance led to the identification
of areas of uncertainty and research gaps, and we identified
priorities for further research in each area. It was also a unique
opportunity to progress towards common European health
policy. Divergent health policies may cause confusion among
the public and the media. The most objective argument
for common health policies consists of a systematic and
transparent search for and evaluation of available evidence.
In 2013, we evaluated the impact of this guidance on the
recommendations for public health management of IMD in
European countries and found out that 90% of the 31 EU
countries or regions found it useful at the national level and
that 50% used it to update their national guidelines within the
three years following the publication of the guidance [32].
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WHO adopted a very similar process for developing
evidence-based immunization recommendations, published
after we initiated this work [21]. Immunization is an area of
public health prevention in which the evidence may also be
indirect (e.g., immunological surrogate for clinical efficacy)
as in our example. GRADE was selected by WHO because
it improves transparency in decision-making, promotes dia-
logue, and provides opportunities to reassess the evidence as
required [21].
2.12. Limitations of the Process. The consortium included
mostly experts in epidemiology and microbiology. It could
have benefited from including clinical experts and members
of patient organization groups, but the short time frame was
already challenging for finalizing the project.
The limited time (6 months) and available resources
imply that our literature reviews could notmeet the standards
of a full systematic review. In addition, we could not cover all
aspects of IMD public health management.
Indeed, the comprehensive application of the GRADE
methodology including exhaustive systematic reviews may
require substantial resources and more time is often required
for rigorous development of guidelines [24]. Thus, in this
project, we applied some strategies of rapid reviews, such
as focusing on existing systematic reviews, having only one
expert for evidence reviews, and limiting the search period
[24]. These may have introduced biases in the selection and
appraisal of studies [24]. However, we enhanced our searches
through inclusion of older studies, searching manually the
references of retrieved studies, not restricting literature
search by language or database, and asking experts for
unpublished data and potentially missed studies. Addition-
ally, though our initial search focused on updating systematic
reviews, we nonetheless retrieved relevant primary studies
to extract all relevant data, if they were not provided in the
systematic reviews. Some authors have suggested that when
the timeframe is limited, combination of electronic searching,
hand searching of relevant reference lists, and consultation
with experts on potentially missed articles may provide
the most comprehensive results [24]. In this regard, WHO
publication on rapid advice guideline—that met similar time
constraints—was a particularly useful reference in helping us
to ensure transparency of the process [14]. It is likely that the
specialist expertise of those performing the review as well as
input from other EU experts minimized the risk that relevant
studies would be missed [24].
We relied mostly on systematic reviews (including one
Cochrane review) for the quality appraisal of individual
studies for Questions B and E [7, 25], but these described
the risk of biases and not the other GRADE criteria for
assigning grades of evidence [11]. In particular we did not
fully appraise bodies of evidence for each outcome for
imprecision, also due to limited instructions in the GRADE
guidance available in 2008 [17]. New guidance published after
our review describes each criterion for appraising evidence
more explicitly, including imprecision [33], allowing further
downgrading for indirectness, imprecision, and reporting
bias [11]. We also did not explicitly define which outcomes
were critical to a decision and which ones were important for
grading overall quality of evidence [24, 34]. It is likely that
the strict application of the newer GRADE guidance could
have led to further downgrading of the quality of evidence for
some of our outcomes, although this may not have changed
our recommendations.
As explained above, one of the challengeswas that we only
found a low quality of evidence (according to GRADE) in
most areas, as evidence from RCTs was only available on the
effectiveness of antibiotic regimes in eradicating carriage.
The GRADE guidance required defining the burden of
the intervention to the patient as well as patients’ values,
preferences, and resource implications to aid in the develop-
ment of recommendations. However, the GRADE guidance
available at the time of developing these recommendations
did not provide a methodology to collect and appraise the
evidence in these areas. We found scarce information in the
literature on the burden, values, and preferences surrounding
interventions and limited data on cost in a few countries, and
these may differ across countries. Although we questioned
EU representatives and twoUK-basedmeningococcal patient
organizations, a representative survey of patients across
Europe would be required for obtaining sound and repre-
sentative evidence. However, we did not have the resources
to initiate a multinational public survey on these issues. Fur-
thermore, the GRADE guidance did not standardize how the
data on burden and values should affect the recommendation;
this is left to deliberation on the part of the decision-making
group and has been criticized as a weakness of the GRADE
process [20]. The updated GRADE guidance also provides a
more structured way to incorporate values and preferences in
the development of recommendations [31].
3. Conclusions
We developed evidence-based guidance on the public health
management of meningococcal disease for EU countries in
a short time frame and with limited resources. A number of
recommendations in this guidance were based on a low qual-
ity of sometimes indirect evidence due to the impracticability
of conducting clinical trials on interventions for outcomes
that are rare or that have become standard practice. However,
the recommendations were generated systematically and
transparently, following GRADE and AGREE standards.This
approach, that explicitly integrates additional criteria with
the quality of evidence, can be usefully applied to the many
areas of public health policy in which quality of evidence is
often low or indirect. A recent survey of European countries
showed that the majority found the guidance based on this
process useful, about half had used the guidance to update
their national recommendations, and a higher proportion of
countries since 2013 compared to that in 2007 recommended
evidence-basedmeasures for IMDpublic healthmanagement
[32].
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